πŸ‡ΊπŸ‡Έ FDA
Patent

US 12391663

Isoindolinone compounds

granted A61PA61P35/00

Quick answer

US patent 12391663 (Isoindolinone compounds) held by Monte Rosa Therapeutics AG expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Monte Rosa Therapeutics AG
Grant date
Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P35/00